Structure

InChI Key LNTHITQWFMADLM-UHFFFAOYSA-N
Smiles O=C(O)c1cc(O)c(O)c(O)c1
InChI
InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)

Physicochemical Descriptors

Property Name Value
Molecular Formula C7H6O5
Molecular Weight 170.12
AlogP 0.5
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 1.0
Polar Surface Area 97.99
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 12.0
Assay Description Organism Bioactivity Reference
Antioxidant activity assessed as superoxide anion radical scavenging activity None 530.0 nM
Inhibition of COX2 at 100 uM by scintillation proximity assay None 30.0 %
Inhibition of NADPH oxidase in LPS-induced mouse BV2 cells assessed as NOX-dependent ROS production at 50 uM Mus musculus 21.5 %
Antiplasmodial activity after 24 hrs against chloroquine-sensitive, mefloquine-resistant Plasmodium falciparum D6 infected human erythrocytes by [G-3H]hypoxanthine uptake Plasmodium falciparum D6 5.0 ug.mL-1
Antibabesial activity against Babesia gibsoni in dog erythrocytes after 72 hrs Babesia gibsoni 13.4 ug.mL-1
Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum FCR3 in human erythrocytes after 24 hrs Plasmodium falciparum 14.8 ug.mL-1
Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins None 10.0 ug.mL-1
Antioxidant activity assessed as DPPH free radical scavenging activity None 3.7 ug.mL-1
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Homo sapiens 3.2 ug.mL-1
Inhibition of soybean 15-lipoxygenase Glycine max 60.5 %
Inhibition of cataracted human eye lens aldose reductase Homo sapiens 97.3 ug.mL-1
Antioxidant activity assessed as DPPH radical scavenging activity after 20 mins None 26.9 ug.mL-1
Antioxidant activity assessed as DPPH radical scavenging activity after 20 mins by UV-visible spectrophotometry None 1.2 ug
Antioxidant activity assessed as DPPH free radical scavenging activity None 5.0 ug.mL-1
Antiinflammatory activity in human neutrophils assessed as respiratory burst inhibition at 1000 ug/ml by WST-1 assay Homo sapiens 42.9 %
Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.50 % after 24 hrs relative to control Staphylococcus aureus 8.7 %
Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.10 % after 24 hrs relative to control Staphylococcus aureus 41.4 %
Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by spectrophotometric analysisic analysis None 1.85 ug.mL-1
Antioxidant activity assessed as DPPH free radical scavenging activity None 3.8 ug
Antioxidant activity assessed as superoxide dismutase-like activity by SOD-WST assay None 6.3 ug.mL-1
Inhibition of porcine pancreatic lipase using micellar solution of triolein as substrate at 1 mM preincubated for 5 mins before substrate addition measured after 30 mins Sus scrofa 4.0 %
Inhibition of mushroom tyrosinase using L-DOPA as substrate at 100 ug/ml after 10 mins Agaricus bisporus 31.7 %
Antioxidant activity assessed as DPPH scavenging activity after 2 hr by spectrophotometry None 2.06 ug.mL-1
Antioxidant activity in phosphate buffer at pH 6.6 assessed as reducing power measuring conversion of potassium ferricyanide to ferrous form after 10 min by spectrophotometry None 5.25 ug.mL-1
Antioxidant activity assessed as DPPH free radical scavenging activity after 20 min by UV-Vis spectrophotometric analysis None 1.28 ug.mL-1
Antioxidant activity assessed as inhibition of DPPH free radicals at 400 uM after 30 min by microplate reader analysis relative to control None 77.68 %
Antioxidant activity assessed as DPPH radical scavenging activity None 6.0 %
Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM Hepatitis GB virus B 97.14 %
Inhibition of ADAM17 alpha-secretase activity in human UI87 cells using amyloid beta precursor protein as substrate at 40 ug/ml after 24 hrs by fluorimetric analysis Homo sapiens 38.9 %
Inhibition of ADAM17 alpha-secretase activity in human UI87 cells using amyloid beta precursor protein as substrate at 30 ug/ml after 24 hrs by fluorimetric analysis Homo sapiens 43.5 %
Inhibition of ADAM17 alpha-secretase activity in human UI87 cells using amyloid beta precursor protein as substrate at 20 ug/ml after 24 hrs by fluorimetric analysis Homo sapiens 47.9 %
Cytotoxicity against rat fibroblast cells Rattus norvegicus 20.0 ug.mL-1
Cytotoxicity against rat epithelial cells Rattus norvegicus 20.0 ug.mL-1
Cytotoxicity against human KB cells Homo sapiens 13.2 ug.mL-1
Antioxidant activity assessed as inhibition of ABTS free radical generation at 9 uM after 20 mins by UV spectrophotometric analysis relative to control None 61.6 %
Antioxidant activity assessed as inhibition of ABTS free radical generation at 17 uM after 20 mins by UV spectrophotometric analysis relative to control None 94.1 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 67.94 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 91.35 %
Inhibition of reduced carboxymethylated-kappa-casein (unknown origin) conversion to amyloid fibrils at 1:0.1 protein to compound molar ratio after 1000 mins by thioflavin T fluorescence assay relative to control Homo sapiens 3.0 %
Inhibition of reduced carboxymethylated-kappa-casein (unknown origin) conversion to amyloid fibrils at 1:0.5 protein to compound molar ratio after 1000 mins by thioflavin T fluorescence assay relative to control Homo sapiens 54.0 %
Inhibition of reduced carboxymethylated-kappa-casein (unknown origin) conversion to amyloid fibrils at 1:1 protein to compound molar ratio after 1000 mins by thioflavin T fluorescence assay relative to control Homo sapiens 87.0 %
Inhibition of reduced carboxymethylated-kappa-casein (unknown origin) conversion to amyloid fibrils at 1:2 protein to compound molar ratio after 1000 mins by thioflavin T fluorescence assay relative to control Homo sapiens 98.0 %
Antioxidant activity of the compound assessed as inhibition of ABTS radicals at 9 uM after 20 mins by spectrophotometric analysis None 61.6 %
Antioxidant activity of the compound assessed as inhibition of ABTS radicals at 17 uM after 20 mins by spectrophotometric analysis None 94.1 %
Antioxidant activity of the compound assessed as inhibition of ABTS radicals at 33 uM after 20 mins by spectrophotometric analysis None 93.9 %
Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate at 100 uM after 30 mins Influenza A virus (A/RI/5+/1957(H2N2)) 3.0 %
Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by UV-spectrophotometry None 8.42 ug.mL-1
Inhibition of insulin fibril formation (unknown origin) assessed as turbidity at 1:5 insulin to compound ratio at pH2 up to 12 hrs by UV/vis spectrometry Homo sapiens 50.0 %
Inhibition of insulin fibril formation (unknown origin) assessed as turbidity at 1:50 insulin to compound ratio at pH2 up to 12 hrs by UV/vis spectrometry Homo sapiens 90.0 %
Antioxidant activity assessed as DPPH free radical scavenging activity measured as decoloration of a MeOH solution after 10 mins by spectrophotometry None 2.79 ug.mL-1
Inhibition of FucT-7 (unknown origin) Homo sapiens 60.0 nM
Antioxidant activity assessed as inhibition of allopurinol-xanthine oxidase system-mediated superoxide formation measured over 7 mins by lucigenin-based chemiluminescence analysis None 700.0 nM
Antioxidant activity assessed as ABTS radical scavenging activity measured after 10 mins by ABTS assay None 350.0 nM
Inhibition of SPI-1 T3SS in Salmonella typhimurium expressing SopE2-CPG2-HA fusion protein assessed as reduction in type 3 protein secretion using Glu-CyFur as substrate at 25 uM after 4 hrs by fluorescence assay Salmonella enterica subsp. enterica serovar Typhimurium 25.0 %
Antioxidant activity assessed as DPPH free radical scavenging activity None 23.7 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -6.43 %
Binding affinity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293 cells assessed as dissociation constant by SPR analysis Homo sapiens 924.0 nM
Binding affinity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293 cells assessed as dissociation rate by SPR analysis Homo sapiens 1.34 10'-3/s
Inhibition of human TAS2R39 expressed in HEK293 cells coexpressing G-protein at 10 mM assessed as reduction in epicatechin gallate-induced intracellular calcium release by Fluo-4-AM dye based fluorescence assay relative to control Homo sapiens 25.0 %
Antioxidant activity assessed as DPPH radical scavenging activity after 5 mins by spectrophotometric analysis None 7.2 ug.mL-1
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 64.71 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 59.39 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 1.29 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 1.29 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.01 %
Inhibition of alpha-synuclein aggregation (unknown origin) at 30 uM incubated for 3 days by thioflavin T based fluorescence assay relative to control Homo sapiens 78.2 %

Related Entries

Cross References

Resources Reference
ChEBI 30778
ChEMBL CHEMBL288114
FDA SRS 632XD903SP
Human Metabolome Database HMDB0005807
Guide to Pharmacology 5549
KEGG C01424
PDB GDE
PubChem 370
SureChEMBL SCHEMBL15012
ZINC ZINC000000001504